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Abstract 
 
Psychostimulants are the first-line treatment in attention deficit/hyperactivity 
disorder (ADHD), but their effects on brain development remain poorly understood. 
In particular, previous structural magnetic resonance imaging (sMRI) studies only 
investigated treatment effects on grey matter (GM) volumes in selected regions of 
interest (ROIs). In this study, voxel-based morphometry (VBM) was used to assess 
medication-related GM volume differences accross the entire brain. Automated 
tracing measurements of selected ROIs were also obtained. Three groups (77 
participants aged 7-to-13 year old) underwent MRI scans and were compared: 
never-medicated children with ADHD (n=33), medicated (methylphenidate) children 
with ADHD (n=20) and typically developing children (TD; n=24). Optimised VBM was 
used to investigate regional GM volumes, controlling for age and gender. Automated 
tracing procedures were also used to assess the average volume of the caudate 
nucleus, the amygdala and the nucleus accumbens. When compared to both 
medicated children with ADHD and TD children, never-medicated children with 
ADHD exhibited decreased GM volume in the insula and in the middle temporal 
gyrus. When compared to TD children, medicated children with ADHD had 
decreased GM volume in the middle frontal gyrus and in the precentral gyrus. 
Finally, ROI analyses revealed a significant association between duration of 
treatment and GM volume of the left nucleus accumbens in medicated children with 
ADHD. In conclusion, this study documents potential methylphenidate-related GM 
volume normalization and deviation in previously unexplored brain structures, and 
reports a positive association between treatment history and GM volume in the 
nucleus accumbens, a key region for reward-processing. 
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Introduction 
 
Psychostimulants such as methylphenidate or amphetamines are the most 
commonly used psychotropic medications in children and adolescents (Zuvekas and 
Vitiello, 2012). In 2008, it was estimated that around 4 million children were treated 
with stimulants each day in the USA (Zuvekas and Vitiello, 2012). Methylphenidate, 
in particular, is the first-line treatment for attention deficit / hyperactivity disorder 
(ADHD) (Biederman and Faraone, 2005). Despite its widespread prescription, an 
ongoing debate exists regarding its long-term effects on the brain, especially 
regarding substance abuse liability (Kim et al., 2009; Volkow 2012). Methylphenidate 
indeed increases dopamine levels in the nucleus accumbens, a pharmacological 
effect underlying drug reward that may trigger the neuroadaptations in dopaminergic 
and glutamatergic signaling associated with addiction (Volkow, 2012). Due in part to 
their impulsivity, children and adolescent with ADHD are known to be at risk for the 
development of substance abuse (Levy et al., 2014). In 2006, a report indicated that 
more than 7 million people in the US had abused ADHD stimulants, and that as 
many as 750000 teenagers may show signs of addiction (Kroutil et al., 2006).  
 In this context, neuroimaging techniques represent valuable tools to track 
down the potential effects of medication on the human brain. In the last two decades, 
several cross-sectional structural magnetic brain imaging (sMRI) studies have 
compared volumes of specific brain regions between children with ADHD who were 
medication-naïve, children with ADHD who had been using methylphenidate, and 
typically developing (TD) children. An early study examined the grey matter (GM) 
volumes of the caudate nucleus, the cerebellum and the four major lobes using 
automated tracing procedures, and reported no significant effect of medication 
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(Castellanos et al., 2002). Subsequent cross-sectional studies examined GM 
volumes of the caudate nucleus (Semrud-Clikeman et al., 2006; Sobel et al., 2010), 
the anterior cingulate cortex (ACC; Semrud-Clikeman et al., 2006), the cerebellum 
(Bledsoe et al., 2009), the thalamus (Ivanov  et al., 2010), the putamen, the globus 
pallidus (Sobel et al., 2010) and the nucleus accumbens (Hoekzema et al., 2014). 
These studies generally reported normalizing effects of medication on GM volume 
deficits found in ADHD patients (Schweren et al., 2012), except for Hoekzema and 
colleagues who found substantial volumetric declines in the bilateral nucleus 
accumbens in medicated patients. However, analysis of longitudinal data suggested 
that this initial reduction was followed by a recovery of volume under maintained 
treatment (Hoekzema et al., 2014). Finally, in a recent longitudinal study, Shaw and 
colleagues examined the volumes of the caudate nucleus, the putamen and the 
globus pallidus in a large cohort of children with ADHD and TD children (Shaw et al., 
2014). They reported no significant association between history of psychostimulant 
treatment and developmental trajectories.  
 Grey matter volumes are only one among different possible indicators of brain 
structure, along with cortical thickness, surface area and cortical gyrification (Winkler 
et al., 2009). One longitudinal study examined change in cortical thickness in 
medicated and never-medicated adolescents with ADHD when compared to TD 
adolescents, and found an excessive rate of cortical thinning in the right motor strip, 
the left middle/inferior frontal gyrus and the right parieto-occipital region in the never-
medicated group only (Shaw et al., 2009). In a larger sample encompassing the 
participants recruited in this study, no significant differences in cortical thickness 
were detected at study entrance when comparing medicated and never-medicated 
children with ADHD, except in a small region in the anterior temporal cortex (Shaw et 
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al., 2006).  
 Taken together, these findings support the view that administration of 
methylphenidate is not detrimental to the development of the human brain 
(Schweren et al., 2013). However, this literature is characterized by several 
limitations. First, despite a preferential activation of prefrontal cortex catecholamine 
neurotransmission by methylphenidate (Spencer et al., 2012), none of these studies 
examined medication effects on GM volumes in frontal regions (only the volume of 
the entire frontal lobe was once examined (Castellanos et al., 2002)). Second, effect 
of methylphenidate on grey matter volume in the nucleus accumbens was only 
examined in children medicated for less than thirteen months (Hoekzema et al., 
2014). Longer treatment durations may be required to identify noticeable structural 
changes in this structure. Third, the above sMRI studies relied on lobar manual or 
automated region of interest (ROI) measurement methods. ROI methods yield a 
single value for the volume of the region examined, obtained after averaging signal 
over the ROI. This signal averaging can cause a dilution of the measure of the 
volume difference, especially when this difference is only present in a limited part of 
the ROI (Voormolen et al., 2009). Voxel-based morphometry (VBM) is an alternative 
automated approach that employs a general linear model framework to conduct 
mass voxel wise statistical tests throughout the brain, allowing it to be a particularly 
sensitive technique for detecting focal differences in GM volumes within all regions of 
the brain (Ashburner and Friston, 2000). VBM has been shown to outperform ROI 
methods when detecting focal differences in morphology (Voormolen et al., 2009). 
However, theoretically, ROI methods remain superior when between-group 
differences are distributed uniformly over a small ROI, since the ROI analysis at this 
spatial scale benefits from substantial signal averaging (Voormolen et al., 2009). 
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Accordingly, both methods can provide different types of information and are thus 
considered as complementary (Giuliani et al., 2005). 
 While no VBM study to date has examined the effects of methylphenidate on 
GM volumes in ADHD patients, two meta-analyses investigated potential effects of 
medication indirectly through meta-regression analyses, based on variations in 
percentage of patients receiving medication included in published VBM studies of 
ADHD. These studies reported a 'normalizing' effect of psychostimulants in the 
caudate nucleus, the ACC and the amygdala (Nakao et al., 2011; Frodl and 
Skohauskas, 2012). Such meta-regression analyses are powerful tools, but due to 
their indirect nature, they are also characterized by intrinsic limitations. Here, for 
example, medication was assessed through the percentage of patients receiving 
medication in past studies, which does not take into account between-study 
variations in treatment duration,  daily dosage, comorbidity rates, gender ratios, pre-
processing options and/or statistical thresholding. Such variations in the underlying 
studies introduce confounds to the meta-analysis. Considering the widespread 
prescription of methylphenidate, more direct approaches should be used to gather 
convergent information and improve our understanding of methylphenidate’s effects 
on brain development. 
 The present sMRI study is the first to use VBM to directly investigate GM 
volume differences in never-medicated children with ADHD, medicated children with 
ADHD and TD children. VBM was used as a first step in an exploratory manner to 
investigate GM volume differences between groups throughout the whole brain. As a 
second step, to improve detection of potential diffuse differences in relevant 
structures of the brain, measurements of three selected ROIs were obtained through 
automated tracing. Only structures of moderate size were selected (Voormolen et al., 
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2009), based on previous findings (Nakao et al., 2011, Frodl and Skohauskas, 2012, 
Hoekzema et al., 2014) and pharmacological plausibility (Volkow, 2012). These ROIs 
were: the caudate nucleus, the amygdala and the nucleus accumbens. We 
hypothesized that medicated children with ADHD would exhibit less pronounced grey 
matter volume reductions than medication-naïve children with ADHD in the caudate 
nucleus and in the amygdala compared to TD children, that no significant between-
group difference would be found in the nucleus accumbens, and that there would be 
a significant correlation between treatment duration and GM volumes in the caudate 
nucleus and in the amygdala in medicated children with ADHD.  
 
Experimental procedures 
 
Participants 
Eighty-four children (44 males) aged 7.3 to 12.9 participated in this study.  
Children with ADHD were recruited from the outpatient clinic in Erasme Hospital, 
Université libre de Bruxelles, Belgium. TD participants were recruited from local 
schools in Brussels or via personal request to professionals working at Erasme 
Hospital. Out of the 84 participants, six children with ADHD were excluded from the 
analysis following the discovery of anatomical brain abnormalities, and one child with 
ADHD was excluded due to excessive motion during MRI scanning. Analyses were 
thus conducted on 77 right-handed children (mean age = 10.2 years; Standard 
deviation (SD) = 1.3 years), comprising 53 children fulfilling DSM-IV-R criteria for the 
ADHD combined type and 24 TD children. The study groups were: TD children 
(n=24, 12 males), subjects with ADHD with a history of long-term treatment with 
stimulants (n=20, 16 males), participants with ADHD who had no history of 
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psychotropic medication treatment (n=33, 18 males). The three groups were 
comparable on age, gender, IQ estimate measured by the age-appropriate Wechsler 
Abbreviated Scale of Intelligence (WASI; Wechsler, 1999) and socio-economic 
status (SES) (Table 2). IQ estimates for medicated children with ADHD were 
obtained off-medication (24h prior). Parental SES was assigned to one of three 
categories (unskilled/qualified worker, clerk/ commercial occupation, and graduate 
occupation) by considering the profession of the most qualified parent. Diagnosis for 
ADHD was based on clinical features including typical history and behavioural report. 
The Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged 
Children-Present and Lifetime Version (K-SADS-PL; Endicott and Spitzer, 1978) was 
completed at screening for each participant to establish the diagnosis according to 
DSM-IV-R criteria in children with ADHD, and to ensure that TD children presented 
no psychiatric condition. Symptoms’ severity in children with ADHD was measured 
using the ADHD rating scale parent form (parents of medicated children were asked 
to rate the behaviour of their child when off-medication) (DuPaul et al., 1998). 
Medicated children with ADHD received between 0.3 and 0.5 mg of methylphenidate 
per kilo (per dose, three times a day) for a minimum of one year (medication duration 
: more than one year, 11 children ; more than 2 years, 7 children ; between 3 and 4 
years, 2 children) and no other medication. All other participants did not receive any 
medication.  
Exclusion criteria for children with ADHD and TD children were presence of a 
psychiatric condition other than ADHD (as assessed by the K-SADS-PL), history of 
prematurity, current or past medical or neurological disorder, contraindication to MRI, 
and IQ estimate under 85. The TD children were naïve for any medication at the time 
of scanning. All subjects lived with their family, and were attending normal primary 
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schools. Each child and her/his parents gave their written consent to participate in 
this study approved by the Ethics Committee of the Erasme University Hospital 
(reference: P2007/332 / B40620072950).  
 
Image acquisition 
Participants were scanned using a 3 Tesla Philips Achieva MRI scanner 
(Philips Healthcare, Best, The Netherlands) with an 8 channel SENSE head coil. A 
high-resolution, 3D T1-weighted structural scan was acquired using a sagittal TFE 
sequence with the following parameters: 160 slices; TR=1960 ms; TE=4.60 ms; 
TI=1040 ms; flip angle=8˚; field of view=250mmx250mm; matrix size=320x320; 
reconstruction interpolated voxel size=0.87x0.87x1.0mm.  
 
Behavioural Data Analyses 
Continuous demographic data were analysed using independent-sample t-
tests and univariate analysis of variance (ANOVA). Categorical demographic data 
were analysed using Chi-Square tests. All analyses were carried out using the 
Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago IL, USA). 
 
 
Voxel-based morphometry analysis  
Data were processed using the Statistical Parametric Mapping Software 
version 8 (SPM8; http://www.fil.ion.ucl.ac.uk/spm/software/spm8; Wellcome 
Department of Imaging Neuroscience, London, UK) and the VBM8 Toolbox. 
Customised tissue probability maps were produced using the matched template 
approach of the Template-O-Matic Toolbox for SPM8, with each participant’s age 
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and gender as defining variables. First, all T1-weighted images were checked for 
scanner- and individual-based artefacts. Individual images were then corrected for 
bias-field inhomogeneities, segmented and spatially normalised (affine-only 
transformation) with reference to customised tissue probability maps. Segmentation 
accuracy was visually checked for each participant. Based on individual registered 
grey matter (GM) and white matter (WM) segmentations, an average DARTEL 
(Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra) 
template of all participants was created in the MNI space (Ashburner et al., 2000). 
The affine-registered GM segments were then warped to this average template using 
the high-dimensional DARTEL approach and modulated. Crucially, the voxel’s signal 
intensity values in the grey matter segments were only multiplied by the non-linear 
component of the registration to account for individual differences in brain size. 
Finally, the GM segments were smoothed using a 5x5x5 mm3 full-width-at-half 
maximal Gaussian kernel (Ashburner et al., 2000).  
Statistical analyses were subsequently performed on a voxel-by-voxel basis 
employing the framework of the general linear model (GLM) within SPM8, with a 
three-group comparison design contrasting the medicated ADHD, never-medicated 
ADHD groups versus the TD group. Using an absolute threshold of 0.1, regionally-
specific between-group differences in grey matter volume were assessed, with 
gender and age as covariates of no interest. Results were examined at the whole 
brain level, and considered significant at the statistical threshold of p<0.001 
uncorrected, using an empirically determined extent threshold of 38 contiguous 
voxels to protect against type 1 error (expected number of voxels according to 
random field theory, i.e. the expected Euler characteristic of the image was used to 
calculate a threshold for the required control of false positives) (Nenadic et al., 
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2010). A mean grey matter volume estimate for each significant cluster was 
extracted using the Marsbar Toolbox. When significant differences involving 
medicated children with ADHD were found, correlations between duration of 
medication and mean grey matter volume estimate within the significant cluster (age 
and gender regressed out) were examined.   
 
ROI analysis  
Total intracranial volume and ROI volumes were estimated using the standard 
automated cortical and subcortical segmentations in Freesurfer 
(http://surfer.nmr.mgh.harvard.edu). Summary images for the outputs were 
generated and inspected to check segmentation quality. We extracted volumes of 
our 6 a priori ROIs (left and right caudate nucleus, amygdala and nucleus 
accumbens) in each of the 77 participants. These volume measurements were 
entered into a GLM (3 groups comparison ANOVA, total intracranial volume 
regressed out), with gender and age as covariates of no interest. Since our design 
included 3 groups, Fisher’s LSD post-hoc tests were conducted following significant 
F-test. In addition, we examined correlations between the volume of each region and 
duration of medication exposure. Because we examined six different a priori regions, 
we performed a bonferroni correction on the p-values resulting from the post-hoc 
tests and correlation analyses (p=0.05/6=0.0083). 
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Results 
 
Demographic characteristics 
Analyses revealed no significant differences between the medicated ADHD, 
never-medicated ADHD and TD groups for gender, IQ, age or SES (Table1). 
Medicated and never-medicated children with ADHD did not differ on ratings of 
ADHD symptoms’ severity (Table1). 
 
****************************************Table 1 here**************************************  
 
 
Voxel-based morphometry  
 
ADHD never-medicated versus TD children: when compared with TD children, 
never-medicated children with ADHD displayed decreased GM volume in the insula 
and in the middle temporal lobe (Table 2). 
ADHD medicated versus TD children: Medicated children with ADHD 
exhibited increased GM volume in the middle frontal gyrus and in the precentral 
gyrus when compared with TD children (Table 2). In medicated children, there was 
no significant correlation between treatment duration and volumes in the middle 
frontal gyrus (r = -.17; p = .45) or in the precentral gyrus (r = -.01; p = .95). 
ADHD medicated versus never-medicated children: When compared to the 
medicated children, the never-medicated children displayed increased GM volume in 
the middle frontal gyrus, and reduced GM volume in the putamen, the insula, the 
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posterior lobe of the cerebellum and the middle temporal gyrus (Table 2). In 
medicated children, there was no significant correlation between treatment duration 
and volumes in the middle frontal gyrus (r = -.28; p = .38), the putamen (first 
coordinate: r = .12; p = .63; second coordinate: r = -.15 ; p = .55), the insula  (r = .05; 
p = .81), the cerebellum (r = -.14; p = .54) or the middle temporal gyrus  (r = -.20; p = 
.39).  
 
*****************************************Table 2 here*************************************  
**************************************** Figure 1 here*************************************  
 
 
 
ROI measurements  
 We found no significant difference between our three groups in any of the 6 a 
priori regions examined (Table3). In medicated children with ADHD, correlational 
analyses revealed a positive and significant correlation between treatment duration 
and GM volume of the left nucleus accumbens area (r = .59; p = .008; Table3; 
Figure1).  
 
***************************************Table 3 here************************************  
 
**************************************Figure 2 here*************************************  
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Discussion 
 
This sMRI study is the first to use VBM to directly compare GM volumes in 
medicated and never-medicated children with ADHD, and TD children. When 
compared to both medicated children with ADHD and TD children, never-medicated 
children with ADHD presented decreased GM volume in the insula and in the middle 
temporal gyrus. When compared to TD children, medicated children with ADHD 
exhibited decreased GM volume in the middle frontal gyrus and in the precentral 
gyrus. Differences in GM volume between medicated and never-medicated children 
with ADHD were also found in the putamen, cerebellum (Medicated > Never-
Medicated) and middle frontal gyrus (Medicated < Never-Medicated). Finally, ROI 
analyses revealed a significant association between duration of treatment and GM 
volume of the left nucleus accumbens in medicated children with ADHD.  
 In this study, GM volume reductions were found in never-medicated children 
with ADHD in the insula and in the middle temporal gyrus when compared both with 
medicated children with ADHD and TD children. In past sMRI studies in ADHD 
relying on ROIs measurements, such a pattern of results was usually interpreted as 
suggesting a ‘normalizing’ effect of methylphenidate on GM volumes (Semrud-
Clikeman et al., 2006; Bledsoe et al., 2009). This interpretation is questionable, for at 
least two reasons. First, ROI analysis relies solely on a single average measure for 
the structure of interest. This averaging may offer an overly simplistic view of 
complex local dynamics involving both increases and decreases in GM volume 
within the structure. Second, cross-sectional designs cannot control for non-
treatment-related differences between medicated and never-medicated groups. Over 
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the years, ADHD has proven to be an extremely heterogeneous disorder, involving 
multiple neural pathways (Villemonteix et al., 2014), which probably explains why 
findings from individual studies examining disorder-related structural deficits have 
been so inconsistent (Nakao et al., 2011). Therefore, never-medicated and 
medicated groups recruited in past cross-sectional studies might present on average 
with different neuropsychological and neurobiological characteristics, which is a 
confounding factor when examining treatment effects.     
 Here, VBM allowed us to investigate GM volume differences within brain 
structures, at the cluster level, which strengthens the interpretation of findings. 
Nevertheless, similarly to all previous sMRI studies of treatment effects on GM 
volumes in ADHD but two (Castellanos et al., 2002; Shaw et al., 2014), our design 
was both naturalistic and cross-sectional. For this reason, while our medicated and 
never-medicated groups both exhibited non-comorbid combined-type ADHD and did 
not differ in levels of symptom’s severity, they may still be characterized on average 
by different disorder-related structural abnormalities. In this context, the relationship 
between group-comparison findings and treatment effects should be discussed 
carefully, based on the convergence of different levels of analysis.   
 The insula is known to be involved in the assessment of motivational and 
rewarding aspects of tasks, as well as in monitoring of task difficulty and 
performance (Ivanov et al., 2014). Interestingly, meta-analyses of functional MRI 
(fMRI) studies reported an altered functioning in this region in patients with ADHD 
during working memory, inhibition and attention tasks (Cortese et al., 2014), and 
found that psychostimulants most consistently increase insula and right inferior 
frontal gyrus activations during stop and time discrimination tasks (Rubia et al., 
2014). Also, increased grey matter volumes in the insula have recently been 
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reported in young occasional users of amphetamine-type psychostimulants such as 
methylphenidate (Mackey et al., 2014). Based on these results, our finding of 
increased grey matter volumes in medicated children with ADHD in the insula when 
compared with never-medicated children with ADHD may be suggestive of a 
structural normalization following chronic methylphenidate administration. In this 
case, the inclusion of a majority of medicated participants may explain why previous 
VBM studies of ADHD did not report grey matter volume reductions in this brain 
region in the patient groups (Nakao et al., 2011).  
ADHD related- middle temporal lobe abnormalities have been reported in the 
past in one fMRI study during a divided attention task (Shafritz et al., 2004), but not 
consistently in meta-analyses (Cortese et al., 2014). Also, methylphenidate 
administration had no direct effect on ADHD-related hypoactivations in this brain 
region (Shafritz et al., 2004). Here, never-medicated children with ADHD presented 
decreased GM volume in the anterior end of the middle temporal lobe (Brodmann 
area 38, temporal pole) when compared to medicated children with ADHD and TD 
children. Reduced cortical thickness in the anterior temporal lobe has been reported 
in the past in adults with childhood ADHD at 33-year follow-up when compared with 
controls, with more pronounced cortical thinning in this region in adults with 
persistent ADHD when compared with the non-ADHD group (Proal et al., 2011). 
Interestingly, in the only previous sMRI study investigating treatment effects at the 
whole brain level, the anterior temporal lobe was the only region showing significant 
differences in cortical thickness between medicated and never-medicated children 
with ADHD (Shaw et al., 2006). Long considered as enigmatic, this part of the 
temporal lobe is thought to be a cortical convergence zone, binding highly processed 
perceptual inputs to visceral emotional responses (Proal et al., 2011). Structural 
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abnormalities in the temporal pole may therefore partly underlie the abnormalities in 
emotional processing found in patients with ADHD (Villemonteix et al., 2014), and 
methylphenidate exposure may contribute to reduce disorder related- structural 
abnormalities in this brain region. 
In the present study, decreased GM volumes were found in the middle frontal 
gyrus (brodmann area 6; premotor cortex) and in the precentral gyrus (brodmann 
area 9) in medicated children with ADHD when compared with TD children. The 
premotor cortex is known to be involved in the planning of complex coordinated 
movements, and decreased grey matter volumes have been found in the past in this 
brain region in children with ADHD (Mostofsky et al., 2002). The precentral gyrus 
(B.A 9) is implicated in multiple executive functions, such as sustained attention, 
working memory and response inhibition (Suskauer et al., 2008). By blocking 
norepinephrine transporters, methylphenidate leads to increased extracellular 
catecholamine levels in frontal regions (Rubia et al., 2014). However, treatment-
related changes in brain activation during cognitive tasks have usually been found in 
inferior frontal regions, as opposed to these middle frontal locations (Rubia et al., 
2014). Therefore, previous literature provides no solid ground to relate these GM 
volume changes to treatment effects. 
When considering these findings, one must note that no significant correlation 
between treatment duration and GM volumes were found in these four brain regions 
in medicated children with ADHD. Due to this lack of convergence between 
correlational analyses and between-group comparisons, we cannot firmly conclude 
that the significant between-group differences represent treatment effects, all the 
more so as our study is the first to directly investigate GM volume differences 
associated with exposure to methylphenidate in these brain regions. Findings should 
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therefore be considered as preliminary until replicated in other VBM studies of 
medication’s effects in ADHD. 
In this study, ROI analyses were also used to improve detection of more 
diffuse structural alterations within brain structures of moderate size (Voormolen et 
al., 2009). This set of analyses yielded one significant finding: in medicated children 
with ADHD, GM volume of the left nucleus accumbens was positively associated 
with treatment duration. In the only previous study investigating methylphenidate 
effects on GM volume in the nucleus accumbens in children with ADHD, Hoekzema 
and colleagues reported an initial bilateral reduction in volume in this region, followed 
by a recovery of volume (Hoekzema et al., 2014). However, children participating in 
this study were all medicated for a maximum of thirteen months (mean duration : 7.5 
months). In our study, treatment durations all exceeded one year. Therefore, our 
findings suggest that longer treatment durations may be associated with increased 
GM volume in the nucleus accumbens, at least in the left part. This would be in line 
with previous studies reporting increases of the left nucleus accumbens volume 
following exposure to amphetamines, especially in young users (Jan et al., 2012). In 
rats, exposure to methylphenidate has also been shown to increase the density of 
dendritic spines of medium-sized spiny neurons in the nucleus accumbens (Kim et 
al., 2009). Finally, in the three-group comparison analysis, there was a non-
significant trend towards increased GM volume in the left nucleus accumbens in 
medicated children with ADHD when compared to both never-medicated children 
with ADHD and TD children (Table3). One can wonder whether longer treatment 
duration may yield a significant result for this contrast.  
Considering the key role played by the nucleus accumbens in addiction 
(Volkow, 2012), methylphenidate-related potential structural changes in this region 
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should be discussed in relation with substance abuse liability. Studies in rodents 
have shown that methylphenidate self-administration enhances the potency and 
reinforcing efficacy of amphetamine-related drugs in the nucleus accumbens 
(Calipari and Jones, 2014), suggesting that methylphenidate may change the 
dopamine system in a way that promotes future drug abuse. Nonetheless, 
development of sensitization and related behaviors depends on the nature of the 
treatment regimen, and it is not clear to what extend drug exposure paradigms in 
rodents mirror the long-term methylphenidate usage in children with ADHD 
(Kuczenski and Segal, 2005). Studies in non-human primates reported no significant 
association between chronic treatment with methylphenidate and vulnerability for 
cocaine addiction, and no medication-related effect on dopamine systems 
development (Volkow, 2012). In humans, most studies seem to find no or possibly 
protective effects of ADHD medication on substance abuse (Humphreys et al., 2013; 
Chang et al., 2014). However, two studies found an association between age of 
initiation of methylphenidate treatment and substance abuse, such as subjects with 
late initiation of stimulant medication (ages 8 to 12) displayed greater substance use 
(Mannuzza et al., 2008; Dalsgaard et al., 2014). In one of these studies, the 
association was found to be mediated by increasing rates of antisocial personality 
disorder diagnosis (Mannuzza et al., 2008).  
Interestingly, increased grey matter volumes in the left nucleus accumbens 
have been reported in individuals displaying antisocial tendencies (Schiffer et al., 
2011). Also, while individuals displaying antisocial tendencies have long been 
thought to exhibit abnormalities in reward processing, impulsive-antisocial traits have 
been found to predict dopamine release and reward anticipation-related neural 
activity in the nucleus accumbens in response to pharmacological and monetary 
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reinforcers (Buckholz et al., 2010). Building on these lines of evidence, one can 
wonder whether methylphenidate related- structural modifications in the left nucleus 
accumbens may subtend abnormalities in reward processing in at least a subset of 
medicated children with ADHD. In line with this hypothesis, animal studies have 
reported abnormalities in reward processing in rodents following exposure to 
methylphenidate (Bolanos et al., 2003, Warren et al., 2012). However, another study 
in rodent suggested that structural alterations of the nucleus accumbens following 
methylphenidate exposure may act as a protective factor against impulsive behavior 
(Leo et al., 2009). More structural and functional brain imaging studies examining 
long term effects of chronic exposure to methylphenidate in the nucleus accumbens 
are needed to clarify this issue. 
Contrary to our hypothesis, we found no GM volume difference between 
never-medicated children with ADHD and TD children in the caudate nucleus or in 
the amygdala, nor treatment effects in these regions. ADHD is a highly 
heterogeneous condition: reduced GM volume in children with ADHD in the caudate 
nucleus are one of the most replicated findings in sMRI studies (Nakao et al., 2011; 
Frodl and Skohauska, 2012), but structural deficits in this region are not expected to 
be found in all subgroups of children with ADHD. Similarly, previous studies have 
been inconsistent regarding treatment effects. Only one meta-analysis reported 
medication-related structural changes in the amygdala (Frodl and Skohauska, 2012), 
and a recent longitudinal study reported no treatment effects in the caudate nucleus 
(Shaw et al., 2014).  
Several methodological limitations should be noted. First, due to the 
exploratory nature of our study, we decided not to apply the most conservative 
statistical thresholding (i.e Family Wise Error Rate correction for multiple 
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comparisons) to our VBM results. Instead, results were considered significant at 
p<0.001 uncorrected, using an empirically determined extent threshold (Nenadic et 
al., 2010). Second, in medicated children, duration of exposure to methylphenidate 
did not exceed four years. Longer exposure may be required to detect significant 
impact on brain structures. Third, GM volumes are only one among many indicators 
of brain development. Future studies should consider medication’s effects over 
longer periods, using longitudinal designs including detailed clinical assessments in 
conjunctions with other indices of structural brain connectivity. This study was also 
characterized by several strengths. First, the use of two complementary approaches 
(VBM and ROI measurements) allowed us to optimally investigate both diffuse and 
focal structural differences between groups (Voormolen et al., 2009). Second, our 
study included the second largest ADHD sample to date when compared with 
previous VBM studies. Third, one must note that all our children with ADHD had no 
comorbid psychiatric disorder. While this means that our sample was somewhat 
different from typical samples of referred children with ADHD showing high rates of 
comorbidity, it also means that children included in our study presented a ‘purest’ 
form of the disorder, possibly leading to a more homogeneous sample than those 
included in previous VBM studies.  
In conclusion, in this cross-sectional study of methylphenidate’s effects on GM 
volumes in ADHD, we report evidence of potential treatment-related GM volume 
normalization in the insula and in the middle temporal gyrus, as well as potential 
neurodevelopmental deviations in the middle frontal and precentral gyri. However, 
due to the cross-sectional nature of our design, these findings should be considered 
as preliminary until replicated. We also document a significant association between 
medication history and GM volume in the left nucleus accumbens, a region known 
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for its key role in reward-processing and addictions. Structural and functional effects 
of methylphenidate in this brain structure undoubtedly deserve further investigation. 
Despite a decade of research, knowledge about methylphenidate’s long term effects 
remain scarce. More structural studies using both cross-sectional and longitudinal 
are needed to gather convergent information and inform public debates on this 
sensitive issue.   
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Figure legends 
 
Figure 1: Statistical Parametric Maps (SPMs) showing foci of significant reduced 
grey matter volume (sagittal and coronal views) among A) the never-medicated 
children with ADHD (n=33) relative to the TD children (n=24) in the insula and in the 
middle temporal gyrus, and B) the medicated children (n=20) with ADHD relative to 
the TD children (n=24) in the middle frontal gyrus and precentral gyrus. 
 
Figure 2: Medicated children with ADHD. Scatter plots showing the positive 
correlation between GM volume of the nucleus accumbens (in cubic millimeters) and 
duration of exposure to methylphenidate (in months). Abbreviations: GM, Grey 
matter. 
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Table 1. Demographic characteristics and brain volumes of participants: Never-medicated ADHD vs. 
Medicated ADHD vs. TD 
  Group  Analysis 
    Measure  1) TD  2) Medicated  
ADHD 
3) Never-
medicated 
ADHD 
  (n=24) (n=20) (n=33)   
    %Male  50% 80% 55%  .09 a 
       
  Mean SD Mean  SD Mean  SD  P-value 
    Age, years  10  1.2 10.4  1.4 10.3  1.4  .47 
    IQ  109.7b 8.6 107.4c 13.5 105.6c 10.7  .43 
    SES  2.6  0.5 2.5  0.7 2.3  0.8  .14 
    ADHD Scores d    39.6 6.8 38 5.4  .36 
Abbreviations: ADHD, Attention-deficit/Hyperactivity Disorder; CSF, Cerebro-spinal fluid; GM, Grey 
matter; IQ, Intelligence quotient; SD, Standard deviation; SES, Socio-economic status; TD, Typically 
developing 
a: Pearson 2 test. Age, IQ and SES were analyzed using Student t-tests, and Total volumes were 
analyzed within  an ANOVA with age and sex as covariates of no interest ; b: two data missing ; c: one 
data missing for each group ; ; d: ADHD Rating Scale-IV home version, parent’s ratings. 
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Table2. Voxel-based morphometry analyses. Whole brain group differences, p < .001 uncorrected, 
with an empirically determined extent threshold of 32 voxels 
 
      Brain region L/R MNI Coordinates k Z – value 
 
TD > Unmed. ADHD  
      
    Insula R 36 3 -12 54 4.08 
    Middle temporal gyrus R 42 21 -41 43 3.79 
 
(TD < Unmed. ADHD) 
      
 
TD > Med. ADHD 
      
    Middle frontal gyrus R 30 -3 63 87 3.64 
    Precentral gyrus R 53 3 27 44 3.48 
 
(TD < Med. ADHD) 
      
 
Med. ADHD > Unmed. ADHD 
      
    Putamen L -32 -12 4 173 4.07 
    Insula R 39 0 -20 130 3.95 
    Putamen L -30 -4 -8 73 3.86 
    Cerebellum, posterior gyrus R 2 -70 -45 66 3.72 
    Middle temporal gyrus R 35 23 -42 58 3.63 
 
Med. ADHD < Unmed. ADHD 
      
    Middle frontal gyrus 
 
L -32 41 30 39 3.63 
Abbreviations: L/R – left/right; MNI- Montreal Neurological Institute; k- cluster size; Med., Medicated; 
Unmed., Unmedicated; TD, Typically Developing. 
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Table3. ROI measures of the caudate nucleus, the amygdala and the nucleus accumbens 
 
Brain 
region 
TD Med. ADHD 
Unmed. 
ADHD 
 
GLM 
results 
 
Correlation 
results 
 Mean SD Mean SD Mean SD  F   r p 
              
Caudate L 3850.8 521.6 4062.9 718.1 4162.4 570.5  1.4 .25  .23 .334 
Caudate R 3920.2 495.9 4135.7 663.2 4193.3 601.2  1.0 .37  .23 .344 
Amygdala L 1725.4 229.4 1795.7 250.5 1754.4 271.9  0.7 .93  .38 .105 
Amygdala 
R 
1806.5 226.6 1967.7 257.6 1937.4 268.3  2.0 .14  .28 .237 
Accumbens 
L 
716.7 152 800.7 124.7 773.6 112.6  2.2 .11  .59 .008 
Accumbens 
R 
791.5 112.7 872.6 150.1 845.6 122.3  1.88 .16  .30 .206 
              Abbreviations: GLM, General Linear Model; L/R – left/right; MNI- Montreal Neurological Institute; k- 
cluster size; Med., Medicated; Unmed., Unmedicated: TD, Typically Developing. Volume is indicated 
in cubic millimeters. For GLM results, group differences between the 3 groups are reported as 
statistics. Individual subject values were covaried in a GLM to account for age and sex, yielding F and 
adjusted p-values. For Correlation results, correlations between GM volume and medication duration 
in medicated children with ADHD (n=20) are reported. P-values significant after applying a bonferroni 
correction are shown in bold.  
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